Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 22-32

  Balandin, Taras G ^a   Edelweiss, Evelina ^a   Andronova, Natalia V ^b   Treshalina, Elena M ^b   Sapozhnikov, Alexander M ^a   Deyev, Sergey M ^a,c  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c INSTITUTE OF GENE BIOLOGY   (Russian Federation)

Author keywords

Antibody; Cancer; ImmunoRNase; Mouse; Ribonuclease; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE 4D5 ANTIBODY DIBARNASE FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; MICE; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RIBONUCLEASES; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79151480850     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9329-2     Document Type: Article

References (39)

1. Moroney SE, Plückthun A (2005) Modern antibody technology: the impact on drug development. In: Knäblein J (ed) Modern biopharmaceuticals. Wiley-VCH, Weinheim, pp 1147-1186
2. MA Olayioye RM Neve HA Lane NE Hynes 2000 The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 3159 3167 1:CAS:528:DC%2BD3cXlt1ajtLY%3D 10.1093/emboj/19.13.3159 10880430
3. M Lacroix G Leclercq 2004 Relevance of breast cancer cell lines as models for breast tumours: an update Breast Cancer Res Treat 83 249 289 1:CAS:528:DC%2BD2cXos1Cisw%3D%3D 10.1023/B:BREA.0000014042.54925.cc 14758095
4. I Hellstrom G Goodman J Pullman Y Yang KE Hellstrom 2001 Overexpression of HER-2 in ovarian carcinomas Cancer Res 61 2420 2423 1:CAS:528: DC%2BD3MXisVSlurk%3D 11289108
5. MF Press C Cordon-Cardo DJ Slamon 1990 Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5 953 962 1:CAS:528:DyaK3cXkvFalsbc%3D 1973830
6. MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
7. HM Shepard P Jin DJ Slamon Z Pirot DC Maneval 2008 Herceptin Handb Exp Pharmacol 181 183 219 1:CAS:528:DC%2BD1cXhslSjtLc%3D 10.1007/978-3-540-73259-4-9 18071947
8. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 1:CAS:528:DC%2BD38XhsVGmt7o%3D 10.1200/JCO.20.3.719 11821453
9. H Burris 3rd D Yardley S Jones G Houston C Broome D Thompson FA Greco M White J Hainsworth 2004 Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 1621 1629 1:CAS:528:DC%2BD2cXpsVWmu7k%3D 10.1200/JCO.2004.08.065 15117984
10. P Nagy E Friedlander M Tanner AI Kapanen KL Carraway J Isola TM Jovin 2005 Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 473 482 1:CAS:528:DC%2BD2MXns1KqsA%3D%3D 15695389
11. EO Serebrovskaya EF Edelweiss OA Stremovskiy KA Lukyanov DM Chudakov SM Deyev 2009 Targeting cancer cells by using an antireceptor antibody- photosensitizer fusion protein Proc Natl Acad Sci U S A 106 9221 9225 1:CAS:528:DC%2BD1MXot1Cgt7Y%3D 10.1073/pnas.0904140106 19458251
12. TA Zdobnova SG Dorofeev PN Tananaev RB Vasiliev TG Balandin EF Edelweiss OA Stremovskiy IV Balalaeva IV Turchin EN Lebedenko VP Zlomanov SM Deyev 2009 Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment J Biomed Opt 14 021004 10.1117/1.3122775 19405717
13. EG Semenyuk OA Stremovskiy EF Edelweiss OV Shirshikova TG Balandin YI Buryanov SM Deyev 2007 Expression of single-chain antibody-barstar fusion in plants Biochimie 89 31 38 1:CAS:528:DC%2BD2sXht1aqtA%3D%3D 10.1016/j.biochi. 2006.07.012 16938381
14. EN Lebedenko TG Balandin EF Edelweiss O Georgiev ES Moiseeva RV Petrov SM Deyev 2007 Visualization of cancer cells by means of the fluorescent EGFP-barnase protein Dokl Biochem Biophys 414 120 123 1:CAS:528: DC%2BD2sXntFKjs7w%3D 10.1134/S1607672907030088 17695317
15. S Kubetzko E Balic R Waibel U Zangemeister-Wittke A Pluckthun 2006 PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting J Biol Chem 281 35186 35201 1:CAS:528: DC%2BD28XhtF2gtbfK 10.1074/jbc.M604127200 16963450
16. EM Glinka EF Edelweiss AM Sapozhnikov SM Deyev 2006 A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells Gene 366 97 103 1:CAS:528:DC%2BD28Xht1CrsLg%3D 10.1016/j.gene.2005.06.042 16300908
17. C Di Paolo J Willuda S Kubetzko I Lauffer D Tschudi R Waibel A Plückthun RA Stahel U Zangemeister-Wittke 2003 A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity Clin Cancer Res 9 2837 2848 12855664
18. SM Deyev R Waibel EN Lebedenko AP Schubiger A Plückthun 2003 Design of multivalent complexes using the barnase barstar module Nat Biotechnol 21 1486 1492 1:CAS:528:DC%2BD3sXpt1Gltb0%3D 10.1038/nbt916 14634668
19. J Willuda S Kubetzko R Waibel PA Schubiger U Zangemeister-Wittke A Plückthun 2001 Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides J Biol Chem 276 14385 14392 1:CAS:528:DC%2BD3MXjt12rt7Y%3D 11278961
20. S Jung A Plückthun 1997 Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting Protein Eng 10 959 966 1:CAS:528:DyaK2sXnsl2kt70%3D 10.1093/protein/10.8.959 9415446
21. E Edelweiss TG Balandin JL Ivanova GV Lutsenko OG Leonova VI Popenko AM Sapozhnikov SM Deyev 2008 Barnase as a new therapeutic agent triggering apoptosis in human cancer cells PLoS ONE 3 e2434 10.1371/journal.pone.0002434 18560598
22. A Knappik A Pluckthun 1995 Engineered turns of a recombinant antibody improve its in vivo folding Protein Eng 8 81 89 1:CAS:528:DyaK2MXksVSjtrc%3D 10.1093/protein/8.1.81 7770457
23. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 55 63 1:STN:280:DyaL2c%2FovFSmtw%3D%3D 10.1016/0022-1759(83)90303-4 6606682
24. N Blin DW Stafford 1976 A general method for isolation of high molecular weight DNA from eukaryotes Nucleic Acids Res 3 2303 2308 1:CAS:528: DyaE28Xltl2ntL0%3D 987581
25. DW Rusnak KJ Alligood RJ Mullin GM Spehar C Arenas-Elliott AM Martin Y Degenhardt SK Rudolph TF Haws Jr BL Hudson-Curtis TM Gilmer 2007 Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines Cell Prolif 40 580 594 1:CAS:528:DC%2BD2sXhtVSksLfP 10.1111/j.1365-2184.2007.00455.x 17635524
26. Z Aguilar RW Akita RS Finn BL Ramos MD Pegram FF Kabbinavar RJ Pietras P Pisacane MX Sliwkowski DJ Slamon 1999 Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells Oncogene 18 6050 6062 1:CAS:528:DyaK1MXntlGitbs%3D 10.1038/sj.onc.1202993 10557094
27. MH Kraus NC Popescu SC Amsbaugh CR King 1987 Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms EMBO 6 605 610 1:CAS:528:DyaL2sXhvFSitL0%3D
28. F Castiglioni E Tagliabue M Campiglio SM Pupa A Balsari S Ménard 2006 Role of exon-16-deleted HER2 in breast carcinomas Endocr Relat Cancer 13 221 32 1:CAS:528:DC%2BD28XltlKku7Y%3D 10.1677/erc.1.01047 16601290
29. Mehta A, Trotta CR (inventors) (2007) PCT Therapeutics Inc., assignee. Methods and agents for screening for compounds capable of modulating HER2 expression. United States patent US2007072186 A1
30. M Jucovic RW Hartley 1996 Protein-protein interaction: a genetic selection for compensating mutations at the barnase-barstar interface Proc Natl Acad Sci USA 93 2343 2347 1:CAS:528:DyaK28XhvVSktrY%3D 10.1073/pnas.93.6.2343 8637875
31. C De Lorenzo G D'Alessio 2008 From immunotoxins to immunoRNases Curr Pharm Biotechnol 9 210 214 10.2174/138920108784567254 18673286
32. J Krauss MA Arndt S Dübel SM Rybak 2008 Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy Curr Pharm Biotechnol 9 231 234 1:CAS:528:DC%2BD1MXisFCksLw%3D 10.2174/138920108784567317 18673289
33. C De Lorenzo A Arciello R Cozzolino DB Palmer P Laccetti R Piccoli G D'Alessio 2004 A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas Cancer Res 64 4870 4874 10.1158/0008-5472.CAN-03-3717 15256457
34. C De Lorenzo C Di Malta G Calì F Troise L Nitsch G D'Alessio 2007 Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent FEBS Lett 581 296 300 10.1016/j.febslet.2006.12.034 17208233
35. ON Ilinskaya S Vamvakas 1997 Nephrotoxic effects of bacterial ribonucleases in the isolated perfused rat kidney Toxicology 120 55 63 1:CAS:528:DyaK2sXjsVGgt7w%3D 10.1016/S0300-483X(97)03639-1 9160109
36. AA Makarov A Kolchinsky ON Ilinskaya 2008 Binase and other microbial RNases as potential anticancer agents Bioessays 30 781 790 1:CAS:528: DC%2BD1cXhtVCqtrnN 10.1002/bies.20789 18623073
37. Karakin EI, Dupal TA, Bochkarev MN, Ivanov VV (1999) Biomonitoring of natural populations of rodentia in Altai regions differing in levels of anthropogenic factors: a problem of development of adequate test system. VOGiS Herald 8: article 6
38. ON Ilinskaya PV Zelenikhin IY Petrushanko VA Mitkevich VS Prassolov AA Makarov 2007 Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response Biochem Biophys Res Commun 361 1000 1005 1:CAS:528:DC%2BD2sXpt1Khu7o%3D 10.1016/j.bbrc.2007.07.143 17689490
39. T Uchida 1970 Properties of ribonuclease T1 in relation to other ribonucleases J Biochem 68 255 264 1:CAS:528:DyaE3MXit1yk 4990608